HBIO Harvard Bioscience, Inc. - Common Stock

NASDAQ · Life Sciences Tools & Services · Lihat di SEC EDGAR ↗
$7,06
Harga · Agu 19, 2026
Fundamental per Agu 11, 2026

Tentang Harvard Bioscience, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Baca selengkapnya

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

History

Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.

The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.

From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.

In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.

The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.

In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).

In 2015 the company acquired HEKA Electronik of Germany.

In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.

In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.

James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.

For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.

In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.

In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.

In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

HBIO Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

Harga
$7.05
Kapitalisasi Pasar
$32M
P/E (TTM)
-0.6
EPS (TTM)
$-1.28
Pendapatan (TTM)
$87M
Imbal Hasil Dividen
ROE
-384.8%
D/E Utang/Ekuitas
2.6
Rentang 52M
$0 – $8

HBIO Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Pendapatan & Laba Bersih $87M
10-point trend, -17.2%
2016-12-31 2025-12-31
EPS $-1.28
8-point trend, -884.6%
2016-12-31 2025-12-31
Arus Kas Bebas $5M
8-point trend, +188.3%
2018-12-31 2025-12-31
Margin -65.5%
10-point trend, +24.5%
2016-12-31 2025-12-31

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik
Tren 5 Tahun
HBIO
Median Rekan
P/E (TTM)
5-point trend, +97.4%
-0.6
31.3
P/S (TTM)
5-point trend, -85.8%
0.4
0.5
P/B
5-point trend, -37.3%
2.3
1.3
EV / EBITDA
5-point trend, -100.7%
-1.2
Price / FCF (Harga / FCF)
5-point trend, -99.9%
5.8

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Metrik
Tren 5 Tahun
HBIO
Median Rekan
Gross Margin (Margin Kotor)
5-point trend, +1.4%
57.7%
47.0%
Operating Margin (Margin Operasi)
5-point trend, -3325.9%
-56.1%
Net Profit Margin (Margin Laba Bersih)
5-point trend, -27195.8%
-65.5%
-11.4%
ROA
5-point trend, -30377.8%
-54.9%
-27.7%
ROE
5-point trend, -106800.0%
-384.8%
-58.6%
ROIC
5-point trend, -3105.0%
-96.8%

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Metrik
Tren 5 Tahun
HBIO
Median Rekan
Debt / Equity (Utang / Ekuitas)
5-point trend, +348.1%
2.6
Current Ratio (Rasio Lancar)
5-point trend, -9.7%
2.2
1.7
Quick Ratio (Rasio Cepat)
5-point trend, -4.1%
1.1

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik
Tren 5 Tahun
HBIO
Median Rekan
Revenue YoY (Pendapatan YoY)
5-point trend, -27.2%
-8.1%
Revenue CAGR 3Y (CAGR Pendapatan 3T)
5-point trend, -27.2%
-8.6%
Revenue CAGR 5Y (CAGR Pendapatan 5T)
5-point trend, -27.2%
-3.2%

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Metrik
Tren 5 Tahun
HBIO
Median Rekan
EPS (Diluted)
5-point trend, -966.7%
$-1.28

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

Metrik
Tren 5 Tahun
HBIO
Median Rekan

HBIO Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

BELI 8 analis
  • Beli Kuat 2 25,0%
  • Beli 4 50,0%
  • Tahan 2 25,0%
  • Jual 0 0,0%
  • Jual Kuat 0 0,0%

Target Harga 12 Bulan

1 analis · 2026-08-16
Target median $7.50 +6,3%
Target rata-rata $7.50 +6,3%

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Kejutan Rata-rata
0.05%
Periode EPS Aktual EPS Estimasi Kejutan
30 Juni 2026 $-0.14 $-0.21 0.07%
31 Maret 2026 $-0.33 $-0.63 0.30%
31 Des. 2025 $0.00 $0.36 -0.36%
30 Sep. 2025 $0.00 $0.05 -0.05%
30 Juni 2025 $-0.10 $-0.10 0.00%
31 Maret 2025 $-0.10 $-0.41 0.31%

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
HBIO $30M -0.5 -8.1% -65.5% -384.8% 57.7%
BNGO $16M -0.3 -7.4% -92.6% -58.8%
CDT
BNBX $6M -0.0 1.1% -709.5% -264.9% 39.3%
TMO $257.86B 32.7 3.9% 15.0% 13.0%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Laba Rugi 17
Data Laporan Laba Rugi Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue 12-point trend, -20.4% $87M $94M $112M $113M $119M $102M $116M $121M $77M $105M $109M $109M
Cost of Revenue 12-point trend, -38.2% $37M $39M $46M $53M $51M $44M $52M $58M $38M $56M $60M $59M
Gross Profit 12-point trend, +1.1% $50M $55M $66M $61M $68M $58M $64M $63M $39M $48M $49M $49M
R&D Expense 12-point trend, +80.8% $9M $10M $12M $12M $11M $9M $11M $11M $6M $5M $6M $5M
SG&A Expense 12-point trend, +5.4% $18M $21M $23M $24M $24M $24M $23M $21M $18M $21M $20M $17M
Operating Expenses 12-point trend, +130.5% $98M $61M $64M $68M $66M $58M $64M $62M $40M $51M $50M $43M
Operating Income 12-point trend, -834.1% $-49M $-6M $2M $-7M $2M $221.0K $377.0K $984.0K $-635.0K $-3M $-2M $7M
Interest Expense 5-point trend, +442.1% · · · · · · · $5M $713.0K $639.0K $846.0K $990.0K
Other Non-op 12-point trend, -134.0% $-3M $-325.0K $-227.0K $302.0K $-666.0K $-806.0K $-469.0K $-4M $-739.0K $-179.0K $-1M $-1M
Pretax Income 12-point trend, -1399.2% $-57M $-12M $-3M $-9M $-140.0K $-7M $-6M $-8M $-3M $-3M $-4M $4M
Income Tax 12-point trend, -133.3% $-686.0K $740.0K $859.0K $337.0K $148.0K $518.0K $-815.0K $-4M $-605.0K $1M $15M $2M
Net Income 12-point trend, -2507.6% $-57M $-12M $-3M $-10M $-288.0K $-8M $-5M $-3M $-865.0K $-4M $-19M $2M
EPS (Basic) 11-point trend, -1928.6% $-1.28 $-0.28 $-0.08 $-0.23 $-0.01 · $-0.12 $-0.08 $-0.02 $-0.13 $-0.57 $0.07
EPS (Diluted) 10-point trend, -1928.6% $-1.28 $-0.28 $-0.08 $-0.23 · · $-0.12 $-0.08 $-0.02 $-0.13 $-0.57 $0.07
Shares (Basic) 12-point trend, +38.0% 44,391,000 43,538,000 42,420,000 41,413,000 40,343,000 38,640,000 37,813,580 36,453,126 34,753,325 34,211,521 33,592,775 32,170,683
Shares (Diluted) 12-point trend, +33.6% 44,391,000 43,538,000 42,420,000 41,413,000 40,343,000 38,640,000 37,813,580 36,453,126 34,753,325 34,211,521 33,592,775 33,236,569
EBITDA 11-point trend, -2736.0% $-49M $-6M $2M $-7M $2M $221.0K $377.0K $984.0K $-101.0K $-3M $-2M ·
Neraca 28
Data Neraca Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, -39.1% $9M $4M $4M $5M $8M $8M $8M $8M $6M $6M $7M $14M
Receivables 12-point trend, -0.6% $16M $15M $16M $17M $22M $18M $21M $21M $13M $16M $18M $16M
Inventory 12-point trend, +1.3% $21M $23M $25M $26M $28M $22M $22M $25M $17M $20M $22M $21M
Other Current Assets 12-point trend, -41.7% $3M $3M $4M $3M $4M $3M $2M $3M $4M $4M $4M $5M
Current Assets 12-point trend, -15.5% $48M $45M $49M $51M $62M $52M $54M $58M $48M $45M $51M $57M
PP&E (Net) 12-point trend, -7.8% $5M $5M $4M $3M $3M $4M $5M $6M $4M $4M $6M $5M
PP&E (Gross) 12-point trend, +13.4% $23M $21M $18M $18M $18M $21M $20M $23M $19M $19M $22M $20M
Accum. Depreciation 12-point trend, +20.7% $18M $16M $14M $15M $14M $17M $15M $17M $16M $15M $16M $15M
Goodwill 12-point trend, -76.0% $10M $56M $57M $56M $58M $59M $57M $57M $36M $38M $40M $40M
Intangibles 12-point trend, -63.9% $8M $11M $16M $21M $27M $33M $38M $46M $10M $17M $21M $21M
Other Non-current Assets 12-point trend, +607.6% $3M $3M $6M $8M $5M $1M $2M $2M $324.0K $128.0K $152.0K $380.0K
Total Assets 12-point trend, -41.1% $80M $127M $137M $145M $162M $156M $165M $169M $109M $108M $120M $136M
Accounts Payable 12-point trend, -42.0% $4M $5M $6M $6M $5M $6M $5M $7M $4M $6M $9M $6M
Accrued Liabilities 6-point trend, +36.8% · · · · · · $6M $7M $4M $5M $4M $4M
Current Liabilities 12-point trend, +21.3% $22M $55M $27M $23M $25M $21M $25M $25M $14M $15M $19M $18M
Capital Leases 7-point trend, -16.3% $7M $6M $5M $5M $6M $7M $8M · · · · ·
Deferred Tax 12-point trend, -76.1% $317.0K $710.0K $776.0K $590.0K $2M $2M $2M $2M $3M $6M $4M $1M
Other Non-current Liabilities 8-point trend, -60.2% $1M $1M $1M $1M $486.0K $3M $749.0K $3M · · · ·
Total Liabilities 12-point trend, +64.0% $66M $63M $64M $73M $79M $80M $83M $86M $28M $36M $42M $40M
Long-term Debt 12-point trend, +67.2% $36M $37M $37M $47M $48M $48M $54M $61M $12M $14M $19M $21M
Total Debt 11-point trend, +118.1% $36M $37M $37M $47M $49M $48M $50M $59M $9M $11M $16M ·
Common Stock 12-point trend, +12.6% $447.0K $441.0K $434.0K $454.0K $452.0K $444.0K $438.0K $436.0K $419.0K $418.0K $416.0K $397.0K
Retained Earnings 12-point trend, -131.7% $-215M $-158M $-146M $-142M $-133M $-132M $-125M $-120M $-117M $-116M $-112M $-93M
Treasury Stock 2-point trend, -100.0% · · · · $0 $11M · · · · · ·
AOCI 12-point trend, -41.8% $-12M $-16M $-14M $-15M $-10M $-13M $-13M $-14M $-11M $-17M $-12M $-8M
Stockholders' Equity 12-point trend, -85.6% $14M $63M $73M $72M $83M $77M $82M $83M $81M $72M $78M $95M
Liabilities + Equity 12-point trend, -41.1% $80M $127M $137M $145M $162M $156M $165M $169M $109M $108M $120M $136M
Shares Outstanding 12-point trend, -86.3% 4,471,989 44,074,475 43,394,509 42,081,707 41,142,876 39,407,080 38,188,208 37,378,802 35,018,478 35,018,478 33,979,265 32,563,256
Arus Kas 16
Data Arus Kas Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Stock-based Comp 12-point trend, -14.0% $2M $4M $5M $4M $4M $4M $3M $3M $4M $3M $3M $2M
Deferred Tax 12-point trend, -139.2% $-553.0K $310.0K $228.0K $-498.0K $-371.0K $-143.0K $-398.0K $-4M $-2M $-279.0K $15M $1M
Amort. of Intangibles 12-point trend, +56.2% $4M $5M $6M $6M $6M $6M $6M $5M $2M $3M $3M $3M
Restructuring 11-point trend, -80.5% $200.0K $800.0K $391.0K $2M $1M $2M $1M · $0 $-4.0K $788.0K $1M
Operating Cash Flow 12-point trend, +54.7% $7M $1M $14M $1M $1M $9M $8M $3M $1M $5M $705.0K $4M
CapEx 9-point trend, +41.3% $1M $3M $2M $2M $1M $1M $1M $986.0K $890.0K · · ·
Investing Cash Flow 12-point trend, +86.2% $-2M $-1M $-2M $-2M $-1M $-1M $-229.0K $-54M $-917.0K $-62.0K $-8M $-14M
Debt Issued 2-point trend, +40000000.00 $40M $0 · · · · · · · · · ·
Net Debt Issued 11-point trend, +283.2% $15M $-6M $-4M $-3M $-4M $-67M $-12M $-20M $-5M $-9M $-8M ·
Stock Issued 5-point trend, +120.6% · · · · · · · $5M $160.0K $182.0K $2M $2M
Net Stock Activity 4-point trend, +123.2% · · · · · · · $5M $160.0K $182.0K $2M ·
Financing Cash Flow 12-point trend, -4.6% $-1M $-131.0K $-12M $-3M $-252.0K $-8M $-8M $53M $-2M $-5M $-540.0K $-1M
Net Change in Cash 12-point trend, +138.7% $5M $-175.0K $-225.0K $-3M $-496.0K $-18.0K $162.0K $2M $137.0K $-1M $-7M $-12M
Taxes Paid 9-point trend, -853.8% $-98.0K $-159.0K $207.0K $534.0K $577.0K $416.0K $374.0K $98.0K $13.0K · · ·
Free Cash Flow 8-point trend, +188.3% $5M $-1M $12M $-438.0K $67.0K $8M $7M $2M · · · ·
Levered FCF · · · · · · · $-995.1K · · · ·
Profitabilitas 8
Data Profitabilitas Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Gross Margin 11-point trend, +28.6% 57.7% 58.2% 58.9% 53.7% 56.9% 56.9% 55.4% 52.3% 46.7% 46.3% 44.8% ·
Operating Margin 11-point trend, -3452.5% -56.1% -6.6% 1.7% -6.1% 1.7% 0.22% 0.32% 0.81% -0.10% -2.9% -1.6% ·
Net Margin 11-point trend, -273.9% -65.5% -13.2% -3.0% -8.4% -0.24% -7.6% -4.0% -2.4% -0.85% -4.1% -17.5% ·
Pretax Margin 11-point trend, -1897.0% -66.3% -12.4% -2.3% -8.1% -0.12% -7.1% -4.7% -6.6% -2.1% -2.9% -3.3% ·
EBITDA Margin 11-point trend, -3452.5% -56.1% -6.6% 1.7% -6.1% 1.7% 0.22% 0.32% 0.81% -0.10% -2.9% -1.6% ·
ROA 11-point trend, -268.9% -54.9% -9.4% -2.4% -6.2% -0.18% -4.9% -2.8% -2.1% -0.80% -3.8% -14.9% ·
ROE 11-point trend, -1649.3% -384.8% -19.3% -4.6% -13.2% -0.36% -10.2% -5.9% -3.6% -1.1% -5.8% -22.0% ·
ROIC 11-point trend, -906.9% -96.8% -6.6% 2.3% -6.0% 3.2% 0.19% 0.24% 0.37% -0.05% -5.0% -9.6% ·
Likuiditas & Solvabilitas 5
Data Likuiditas & Solvabilitas Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, -15.7% 2.2 0.8 1.8 2.2 2.4 2.5 2.1 2.7 3.4 3.1 2.6 ·
Quick Ratio 11-point trend, -10.3% 1.1 0.3 0.8 0.9 1.2 1.2 1.1 1.4 1.6 1.5 1.3 ·
Debt / Equity 11-point trend, +1132.0% 2.6 0.6 0.5 0.7 0.6 0.6 0.6 0.7 0.1 0.2 0.2 ·
LT Debt / Equity 11-point trend, +1132.0% 2.6 0.0 0.4 0.6 0.5 0.6 0.6 0.7 0.1 0.2 0.2 ·
Interest Coverage 4-point trend, +109.1% · · · · · · · 0.2 -0.1 -4.7 -2.0 ·
Efisiensi 3
Data Efisiensi Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, -1.3% 0.8 0.7 0.8 0.7 0.7 0.6 0.7 0.9 0.9 0.9 0.8 ·
Inventory Turnover 11-point trend, -40.5% 1.7 1.6 1.8 1.9 2.1 2.0 2.2 2.7 2.6 2.7 2.8 ·
Receivables Turnover 11-point trend, -13.2% 5.6 6.1 6.8 5.9 6.0 5.3 5.5 6.9 6.4 6.3 6.5 ·
Per Saham 5
Data Per Saham Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, -86.6% $0.31 $1.44 $1.68 $1.72 $2.03 $1.95 $2.14 $2.21 $2.31 $2.10 $2.28 ·
Revenue / Share 11-point trend, -39.7% $1.95 $2.16 $2.65 $2.74 $2.95 $2.64 $3.07 $3.31 $2.93 $3.06 $3.23 ·
Cash Flow / Share 11-point trend, +621.9% $0.15 $0.03 $0.33 $0.03 $0.03 $0.24 $0.21 $0.08 $0.03 $0.16 $0.02 ·
Cash / Share 11-point trend, -3.0% $0.19 $0.09 $0.10 $0.11 $0.19 $0.21 $0.22 $0.22 $0.16 $0.16 $0.20 ·
EPS (TTM) 11-point trend, -1928.6% $-1.28 $-0.28 $-0.08 $-0.23 · $-0.21 $-0.12 $-0.08 $-0.02 $-0.13 $-0.57 $0.07
Tingkat Pertumbuhan 3
Data Tingkat Pertumbuhan Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -149.0% -8.1% -16.1% -0.96% -4.7% 16.5% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -367.9% -8.6% -7.5% 3.2% · · · · · · · · ·
Revenue CAGR 5Y -3.2% · · · · · · · · · · ·
Valuasi (TTM) 13
Data Valuasi (TTM) Tahunan untuk HBIO
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, -20.4% $87M $94M $112M $113M $119M $102M $116M $121M $77M $105M $109M $109M
Net Income TTM 12-point trend, -2507.6% $-57M $-12M $-3M $-10M $-288.0K $-8M $-5M $-3M $-865.0K $-4M $-19M $2M
Market Cap 11-point trend, -74.6% $30M $93M $232M $117M $290M $169M $116M $119M $116M $105M $118M ·
Enterprise Value 11-point trend, -55.2% $57M $126M $265M $159M $331M $209M $158M $169M $119M $111M $128M ·
P/E 11-point trend, -100.6% -0.5 -7.5 -66.9 -12.0 · -20.4 -25.4 -39.8 -165.0 -23.5 -6.1 81.0
P/S 11-point trend, -68.1% 0.3 1.0 2.1 1.0 2.4 1.7 1.0 1.0 1.5 1.0 1.1 ·
P/B 11-point trend, +43.6% 2.2 1.5 3.2 1.6 3.5 2.2 1.4 1.4 1.4 1.5 1.5 ·
P / Cash Flow 11-point trend, -97.3% 4.5 64.6 16.5 101.2 229.8 18.1 14.5 41.2 109.3 19.5 167.2 ·
P / FCF 8-point trend, -91.3% 5.5 -77.2 19.0 -266.1 4329.2 20.7 17.1 62.6 · · · ·
EV / EBITDA 11-point trend, +98.4% -1.2 -20.3 139.8 -23.0 160.1 945.8 419.8 172.2 -1176.3 -37.0 -74.5 ·
EV / FCF 8-point trend, -88.3% 10.5 -104.8 21.6 -363.4 4938.0 25.6 23.2 89.3 · · · ·
EV / Revenue 11-point trend, -43.7% 0.7 1.3 2.4 1.4 2.8 2.0 1.4 1.4 1.5 1.1 1.2 ·
Earnings Yield 11-point trend, -15631.7% -191.0% -13.3% -1.5% -8.3% · -4.9% -3.9% -2.5% -0.61% -4.3% -16.4% 1.2%

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Laporan Laba Rugi
2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $87M$94M$112M$113M$119M
Margin Kotor % 57.7%58.2%58.9%53.7%56.9%
Margin Operasi % -56.1%-6.6%1.7%-6.1%1.7%
Laba Bersih $-57M$-12M$-3M$-10M$-288.0K
EPS Dilusian $-1.28$-0.28$-0.08$-0.23
Neraca
2025-12-312024-12-312023-12-312022-12-312021-12-31
Utang / Ekuitas 2.60.60.50.70.6
Rasio Lancar 2.20.81.82.22.4
Rasio Cepat 1.10.30.80.91.2
Arus Kas
2025-12-312024-12-312023-12-312022-12-312021-12-31
Arus Kas Bebas $5M$-1M$12M$-438.0K$67.0K

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

📊

Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Pemilik institusional (13F) 9 pengaju · $5.5M total · Per tanggal 30 Juni 2026

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
0 (0 vs Kuartal sebelumnya) 0 (-57 vs Kuartal sebelumnya) 2 (+2 vs Kuartal sebelumnya) 0 (-3 vs Kuartal sebelumnya) +90K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
AMH Equity Ltd $1.774.844 4.047.535 32,20% Saham
Meros Investment Management, LP $1.125.401 182.992 20,41% Saham
VANGUARD GROUP INC $1.092.570 1.633.139 19,82% Saham
NANO CAP NEW MILLENNIUM GROWTH FUND L P $879.954 143.082 15,96% Saham
TWO SIGMA ADVISERS, LP $587.578 878.556 10,66% Saham
Nuveen Asset Management, LLC $40.837 19.354 0,74% Saham
Point72 Asia (Singapore) Pte. Ltd. $6.445 14.697 0,12% Saham
WOLVERINE TRADING, LLC $5.102 11.600 0,09% Opsi beli
Financial Connections Group, Inc. $0 30 0,00% Saham

Orang dalam perusahaan 35 orang dalam · 14 pejabat · 18 direktur

Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
John D Duke Chief Executive Officer 20 Maret 2026 A 180.000 1 0 $25.050
Jeffrey Duchemin Chief Executive Officer 7 Juli 2019 D 464.528 0 0 $0
Mark T Frost Chief Financial Officer 20 Maret 2026 A 47.500 1 0 $25.000
Jennifer Cote Chief Financial Officer 19 Maret 2025 F 159.019 0 0 $0
Michael A. Rossi Chief Financial Officer 29 Des. 2022 F 260.540 0 0 $0
Kamalam Unninayar Chief Financial Officer 7 Maret 2019 A 73.858 0 0 $0
Bryce Anthony Chicoyne Chief Financial Officer 1 Mei 2007 A 0 0 $0
Mark A Norige President, Harvard Apparatus 1 Mei 2007 A 0 0 $0
David L Strack President of Subsidiary 25 Mei 2005 A 0 0 $0
Kenneth Fletcher Olson Chief Operating Officer 29 Des. 2021 F 155.595 0 0 $0
Yash Singh Executive Vice President 31 Okt. 2019 A 39.286 0 0 $0
Yong Sun VP - Commercial Operations 1 Jan. 2019 F 242.805 0 0 $0
Yoav Sibony VP - Global Sales 3 Agu 2015 A 21.582 0 0 $0
Paul Bailey VP, Finance & Admin. 25 Mei 2005 A 0 0 $0
Seth Benjamin Benson Direktur 9 Juni 2026 A 27.556 0 0 $0
Katherine A. Eade Direktur 9 Juni 2026 A 58.669 0 0 $0
Robert E. Gagnon Direktur 9 Juni 2026 A 27.556 0 0 $0
William Snider Direktur 9 Juni 2026 A 48.556 2 0 $103.604
Stephen J Denelsky Direktur 9 Juni 2026 A 37.556 1 0 $48.700
James W Green Direktur 15 Agu 2025 D 2.452.566 0 0 $0
Thomas W Loewald Direktur 21 Mei 2024 A 295.311 0 0 $0
Bertrand Loy Direktur 21 Mei 2024 A 56.575 0 0 $0
Alan I Edrick Direktur 21 Mei 2024 A 273.911 0 0 $0
John F Kennedy Direktur 23 Maret 2021 G 323.344 0 0 $0
Susan M. Steele Direktur 4 Jan. 2021 A 49.400 0 0 $0
George Uveges Direktur 12 Maret 2018 M 142.685 0 0 $0
Earl R Lewis Direktur 2 Jan. 2018 A 477.050 0 0 $0
David Green Direktur 7 Feb. 2017 S 925.571 0 0 $0
Neal J Harte Direktur 25 Mei 2016 M 106.399 0 0 $0
Robert A Dishman Direktur 28 April 2015 A 51.055 0 0 $0
Chane Graziano Pemilik 10% 7 Nov. 2013 G 3.005.150 0 0 $0
HARVARD BIOSCIENCE INC Pemilik 10% 1 Nov. 2013 J 0 0 0 $0
HSO LIMITED PARTNERSHIP Pemilik 10% 16 Mei 2008 S 2.757.257 0 0 $0
Thomas Mcnaughton 1 Nov. 2013 J 171.613 0 0 $0
Susan M Luscinski 1 Nov. 2013 J 469.720 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Aktivis & pemilik 5%+ 5 saham

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider 23 Maret 2026 15,97% Pengajuan awal SEC
ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 pengajuan 22 Juni 2020 Pengajuan awal SEC
HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 pengajuan 20 Mei 2008 Pengajuan awal SEC
14 Des. 2007 Pengajuan awal SEC
Orang pelapor yang tidak diungkapkan 29 Juli 2002 Pengajuan awal M&A / penjualan SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Kepemilikan ETF Dimiliki oleh 2 ETF

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
VXF · VANGUARD INDEX FUNDS 0,00% 42.043 SH 8 Agu 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,00% 123.470 SH 8 Agu 2026 Harian